An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Acronyms pathfinder6
- Sponsors Novo Nordisk
- 14 Feb 2018 Planned End Date changed from 1 Nov 2021 to 13 Nov 2021.
- 14 Feb 2018 Planned primary completion date changed from 1 Nov 2021 to 13 Nov 2021.
- 10 Jun 2017 Biomarkers information updated